Stock 688670 JIANGSU GDK BIOLOGICAL TECHNOLOGY CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Jiangsu Gdk Biological Technology Co., Ltd

Equities

688670

CNE100004NR4

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
17.5 CNY -0.34% Intraday chart for Jiangsu Gdk Biological Technology Co., Ltd +3.49% -38.51%
Apr. 15 Jiangsu Gdk Biological Technology Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
2023 Jiangsu Gdk Biological Technology Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025
Capitalization 1 6,660 3,783 3,506 2,156 -
Enterprise Value (EV) 1 6,660 3,783 3,506 2,156 2,156
P/E ratio 68.8 x 91.5 x -49.1 x 6.55 x 5.22 x
Yield - - - - -
Capitalization / Revenue 16,977,586 x - - - -
EV / Revenue 16,977,586 x - - - -
EV / EBITDA 58,847,022 x - - - -
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book 4.56 x - - - -
Nbr of stocks (in thousands) 123,200 123,200 123,200 123,200 -
Reference price 2 54.06 30.71 28.46 17.50 17.50
Announcement Date 2/25/22 4/19/23 4/15/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net sales - 392.3 - - - -
EBITDA - 113.2 - - - -
EBIT - 83.97 - - - -
Operating Margin - 21.41% - - - -
Earnings before Tax (EBT) - 84 - - - -
Net income 1 155 82.46 41.54 -70.99 328.8 413
Net margin - 21.02% - - - -
EPS 2 1.679 0.7857 0.3357 -0.5800 2.670 3.350
Free Cash Flow - - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 7/12/21 2/25/22 4/19/23 4/15/24 - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) - 10.9% - -5.02% 17.7% 19.1%
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share - 11.90 - - - -
Cash Flow per Share - 0.8400 - - - -
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 7/12/21 2/25/22 4/19/23 4/15/24 - -
1CNY in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
17.5
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
JIANGSU GDK BIOLOGICAL TECHNOLOGY CO., LTD Stock Jiangsu Gdk Biological Technology Co., Ltd
-38.51% 298M
CSL LIMITED Stock CSL Limited
-3.79% 88.14B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.45% 40.51B
BIOGEN INC. Stock Biogen Inc.
-15.94% 31.67B
UCB Stock UCB
+52.66% 24.62B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-14.50% 15.65B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.12% 11.97B
INCYTE CORPORATION Stock Incyte Corporation
-14.38% 12.07B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-42.56% 11.61B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+4.87% 8.81B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 688670 Stock
  4. Financials Jiangsu Gdk Biological Technology Co., Ltd